Medpace Holdings, Inc.
MEDP
$332.81
$7.082.17%
| Weiss Ratings | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B | |||
| Rating Factors | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.12 | |||
| Price History | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.96% | |||
| 30-Day Total Return | -4.34% | |||
| 60-Day Total Return | -5.06% | |||
| 90-Day Total Return | 1.44% | |||
| Year to Date Total Return | -0.58% | |||
| 1-Year Total Return | -18.75% | |||
| 2-Year Total Return | 66.98% | |||
| 3-Year Total Return | 124.01% | |||
| 5-Year Total Return | 267.46% | |||
| 52-Week High % Change | -29.15% | |||
| 52-Week Low % Change | 7.85% | |||
| Price | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $459.77 | |||
| 52-Week Low Price | $302.01 | |||
| 52-Week Low Price (Date) | Oct 22, 2024 | |||
| 52-Week High Price (Date) | Jul 17, 2024 | |||
| Valuation | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 9.92B | |||
| Enterprise Value | 9.40B | |||
| Price/Earnings (TTM) | 25.78 | |||
| Earnings Per Share (TTM) | 12.63 | |||
| Earnings Per Share Growth | 42.24% | |||
| Price/Earnings To Growth | 0.61 | |||
| Price/Sales (TTM) | 4.92 | |||
| Price/Book (Q) | 12.06 | |||
| Enterprise Value/Revenue (TTM) | 4.46 | |||
| Price | $332.81 | |||
| Enterprise Value/EBITDA (TTM) | 19.75 | |||
| Enterprise Value/EBIT | 21.04 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 31.87M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (513) 579-9911 | |||
| Address | 5375 Medpace Way Cincinnati, OH 45227 | |||
| Website | www.medpace.com | |||
| Country | United States | |||
| Year Founded | 1992 | |||
| Profitability | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 21.18% | |||
| Profit Margin | 19.17% | |||
| Management Effectiveness | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 14.87% | |||
| Return on Equity | 58.42% | |||
| Income Statement | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.11B | |||
| Total Revenue (TTM) | 2.11B | |||
| Revenue Per Share | $66.17 | |||
| Gross Profit (TTM) | 1.43B | |||
| EBITDA (TTM) | 476.12M | |||
| EBIT (TTM) | 446.87M | |||
| Net Income (TTM) | 404.39M | |||
| Net Income Avl. to Common (TTM) | 404.39M | |||
| Total Revenue Growth (Q YOY) | 7.66% | |||
| Earnings Growth (Q YOY) | 49.45% | |||
| EPS Diluted (TTM) | 12.63 | |||
| EPS Diluted Growth (Q YOY) | 49.22% | |||
| Balance Sheet | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 669.44M | |||
| Cash Per Share (Q) | $21.00 | |||
| Total Current Assets (Q) | 1.03B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 825.55M | |||
| Current Ratio (Q) | 0.932 | |||
| Book Value Per Share (Q) | $27.01 | |||
| Total Assets (Q) | 2.10B | |||
| Total Current Liabilities (Q) | 1.10B | |||
| Total Debt (Q) | 149.52M | |||
| Total Liabilities (Q) | 1.28B | |||
| Total Common Equity (Q) | 825.55M | |||
| Cash Flow | MEDP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -28.31M | |||
| Cash from Financing (TTM) | -154.01M | |||
| Net Change in Cash (TTM) | 423.99M | |||
| Levered Free Cash Flow (TTM) | 464.59M | |||
| Cash from Operations (TTM) | 608.82M | |||
